Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
      • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Multiple Sclerosis
  • Systemic Sclerosis
Research Spotlight
  • New clinical practice guidelines for treating multiple myeloma

    May 2019

  • MRD-negative status prognostic for PFS and OS for patients with multiple myeloma

    March 2019

  • Delayed Auto-HCT Can Lead to Inferior Survival Rates in Patients with MM

    May 2018

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Multiple Myeloma
  • Email
  • Print This Page

Related Resources

  • HCT Guidelines App
  • Subscribe to the Latest Research
  • All Outcomes and Trends Data

Patient Resources

  • Understanding Bone Marrow Transplant Outcomes
  • Transplant and Multiple Myeloma (PDF)
  • Transplant Basics Booklet
  • Transplant Basics Videos

Multiple Myeloma

Approximately 30,000 individuals are diagnosed with multiple myeloma in the United States each year, with a median age at diagnosis of 69 years. [1]

Multiple myeloma is the most common indication for hematopoietic cell transplantation (HCT) in the United States. Approximately 96% of transplants in patients with multiple myeloma are autologous transplants, according to the Center for International Blood and Marrow Transplant Research® (CIBMTR®), our research program. [2]

Initial treatment for patients with multiple myeloma is typically a course of induction therapy, followed by autologous HCT in eligible patients. Allogeneic transplantation for multiple myeloma is generally reserved for patients with high-risk disease and the majority performed after an autologous HCT with reduced-intensity or non-myeloablative conditioning regimens. [2,3]

Advances

Recent research in multiple myeloma provides new data for clinical decision-making and treatment advances in this older patient population, including:

  • Using reduced-intensity conditioning allogeneic HCT [4]
  • Exploring the benefit of tandem auto/auto or auto/allo transplants - autologous HCT followed by either a second autologous HCT or a reduced-intensity allogeneic HCT [4,5,6]
  • Using IMID-class drugs such as thalidomide and lenalidomide, proteasome inhibitors such as bortezomib and carfilzomib, and other novel drugs as part of initial or subsequent treatment or as maintenance therapy following HCT [3]

Outcomes

Review outcomes for autologous and allogeneic transplantation in patients with multiple myeloma below. View additional multiple myeloma slides showing demographic data and transplant trends.

Data in this section have been prepared by CIBMTR.

Figure 1: Multiple Myeloma Survival, HCT, by Donor Type

Multiple Myeloma Survival, HCT, by Donor Type

Download slide "Multiple Myeloma Survival, HCT, by Donor Type"

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [7] 

Transplant Consultation Guidelines: Multiple Myeloma

  • At diagnosis
  • At progression and/or relapse

Download as a slide (PPT)

  • At diagnosis
  • At progression and/or relapse

Transplant Consultation Guidelines: Light Chain Amyloidosis

  • At diagnosis
  • At progression and/or relapse

Transplant Consultation Guidelines: POEMS Syndrome (Osteosclerotic Myeloma)

  • At diagnosis
View complete Referral Timing Guidelines

 

Transplant Consultation Guidelines: Light Chain Amyloidosis

References

  1. SEER Stat Fact Sheets: Myeloma. Accessed 9 March, 2018. Access
  2. D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017. Available at: http://www.cibmtr.org
  3. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008; 111(6): 2962-2972. Access
  4. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009; 23(3): 442-448. Access
  5. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial. Lancet Oncol. 2011; 12(13): 1195-1203. Access
  6. Gahrton G, Iacobelli S, Björkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: Long-term results of the EBMT-NMAM2000 study. Blood. 2013; 121(25): 5055-5063. Access
  7. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright